Sky Century Investment (SKYI) Asset Utilization Ratio (2025 - 2026)
Sky Century Investment (SKYI) posted quarterly Asset Utilization Ratio of 1.06 for Q2 2026, up 64.72% year-over-year from 0.65 in Q2 2025, and little changed quarter-over-quarter from 1.07 in Q1 2026.
Sky Century Investment (SKYI) Asset Utilization Ratio (2025 - 2026) Analysis & Trends
Sky Century Investment (SKYI) has reported Asset Utilization Ratio for 2 consecutive years, with 1.06 the latest figure, recorded in Q2 2026.
- In Q2 2026, Asset Utilization Ratio rose 64.72% year-over-year to 1.06; the TTM figure through May 2026 stood at 1.06 (up 64.72% YoY), while the FY2025 annual figure was 0.74, down 31.77% from the prior year.
- Asset Utilization Ratio held at 1.06 in Q2 2026 per SKYI's latest filing, from 1.07 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 1.07 in Q1 2026 and bottomed at 0.65 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 0.43 |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 0.63 |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 0.47 |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 0.45 |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 0.41 |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 0.66 |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 0.37 |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Sky Century Investment | 393,547.71 | 393,283.71 | 26,045.00 | 1.06 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 1.06 |
| Feb 28, 2026 | 1.07 |
| Nov 30, 2025 | 0.79 |
| Aug 31, 2025 | 0.65 |
| May 31, 2025 | 0.65 |